Special Topics in Pain: Opioids

Release Date: May 02, 2018
Expiration Date: May 02, 2020

This educational activity is provided by Dannemiller
Dannemiller

Intended Audience

Physicians, Registered Nurses, CRNAs, Pharmacist

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Review and evaluate the latest advances and newest information in the area of Local Anesthetics.
  • Review and evaluate the latest advances and newest information in the area of Opioids.
  • Review and evaluate the latest advances and newest information in the area of Economic considerations.
  • Review and evaluate the latest advances and newest information in the area of Risk and prognostic scales.
  • Review and evaluate the latest advances and newest information in the area of Steroids.
  • Review and evaluate the latest advances and newest information in the area of Psychopharmacologics.
  • Review and evaluate the latest advances and newest information in the area of Psychology of specific Groups (e.g. veterans, elderly, Children, war zones, Third world nations).
  • Review and evaluate the latest advances and newest information in the area of other (unspecified) systems.
  • Review and evaluate the latest advances and newest information in the area of Intravenous Agents.
  • Review and evaluate the latest advances and newest information in the area of Forms of Psychotherapy.
  • Review and evaluate the latest advances and newest information in the area of Psychological and Pain Scales.
  • Review and evaluate the latest advances and newest information in the area of Legal considerations.
  • Review and evaluate the latest advances and newest information in the area of Endocrine System.
  • Review and evaluate the latest advances and newest information in the area of Adrenergic antagonists.

Statement of Need

This program is designed to assist anesthesia and pain team-members in the area of Opioids.

Method of Participation

This activity should take approximately 3 hour to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through May 1, 2020. No credit will be given after this date. 

In the event you have questions about this activity or are unable to retrieve the certificate, please email cme@dannemiller.com and a certificate will be emailed within 2 weeks.

System requirements

  • Computer, tablet, or smartphone with internet access
  • Web browser (Chrome, Firefox, IE 8+) with javascript enabled

Accreditation

In support of improving patient care, Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Dannemiller designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nurses

Dannemiller designates this educational activity for 3.0 contact hours.

Nurse Anesthetists

Pharmacists

Dannemiller has assigned 3.00 contact hours 3.00 CEUs) of continuing pharmacy education credit to this activity. ACPE program number 0522-.

Faculty

Abstractors and their disclosures are identified at the onset of each abstract.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

Dr. Brian Boise, MD, content reviewer, and Barbra Thompson, Dannemiller project manager have no financial relationships with commercial interests.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

Off-label statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

Begin this activity